Term Definition A transfer of Value A transfer of value is a transfer of some form of value or benefit from GSK to a Healthcare Organisation (HCO). A transfer of value can be made directly from GSK or indirectly via an intermediary and can be a monetary payment.	1.1
Professional (HCP) or Healthcare Organisation (HCO). A transfer of value can be modified directly from GSK or indirectly via an intermediary and can be a monetary payment	ithcare
directly from GSK or indirectly via an intermediary and can be a monetary payment	
as a fee for service) or a non-monetary benefit (such as a flight or a registration fee	9
where the money is paid to a travel agent or event organiser).	
Global Corporation The report contains all transfers of value from all GSK entities to the Luxembourg	
vs Legal entities HCP/HCOs. The transfers of value which were initiated by an international GSK ent	tity
towards a Luxembourg HCP/HCO are also integrated in this report. GSK issues one	report
per country showing all transfers of value made to HCPs / HCOs in that country by	
Pharmaceuticals, GSK Vaccines, GSK Consumer Healthcare, and by ViiV Healthcare.	
Domicile reporting GSK will report transfers of value in the country in which the HCP/ HCO has their pr	-
practice, that report will include all transfers of value made by GSK anywhere in the	e
world.	1
HCP Consent For HCPs, the external disclosure report will include transfers of value only if the H	
consented to disclosure. If consent has not been given or was withdrawn, transfer	
value for that HCP will be disclosed on an aggregate basis that does not identify the	
recipient HCP. The detail of those transfers of value is shown in the statement whi	ch is
sent to the HCP, but not in the published report. HCPs employed by GSK will not report payments made to HCPs who are employed by GSK as staff mer	mhors
GSK GSK considers that it would be inappropriate to disclose an employee's salary, bon	
expenses and benefits.	us,
Reporting period The external disclosure report contains all transfers of value made in the calendary	vear
2015. Monetary transfers of value of activities which have taken place in 2014 but	
were paid in 2015 are also included in the report.	
Reporting date GSK has defined two types of transfers of value for Reporting Date purposes:	
 a Monetary transfer of value is a payment of money made to a HCP/HCO b 	v GSK
either directly or through an intermediary (for example, fees for service).	•
Reporting Date for these transfers of value will be the actual payment date	
irrespective of when the event happened (for example, when a consultance	y fee is
paid, not when the work took place).	
 a Non-monetary transfer of value is a benefit received from GSK either dire 	ectly or
through an intermediary without a monetary payment (a flight or a congre	
registration fee paid to a travel agent or events organiser, for example). The	
Reporting Date for these transfers of value will be the event date (for exam	nple,
when the congress took place).	
Value added Tax GSK has taken the decision to report values including VAT wherever possible due to	
(VAT) complexity of VAT regimes around Europe and the inconsistency of whether VAT may not be reimbursely depending on where the transaction took place and the	
may not be reimbursable depending on where the transaction took place and the of residency of the HCP or HCO. All other taxes are included in the reported values.	-
amount including VAT is not available, the net amount is disclosed.	. II tile
Currency GSK records transfers of value in the currency in which the transaction took place a	and
converts these. The report visible shows all values in EURO.	ariu
Novartis On 2 March 2015, GSK and Novartis completed a three part transaction, as a result	of
methodology which GSK acquired Novartis' global Vaccines business (excluding influenza vaccine	
created a new world leading Consumer Healthcare joint venture with Novartis; and	
divested its Oncology business to Novartis. In respect of the Oncology business	
transferred to Novartis, we are not disclosing any transfers of value for which the	
Reportable Date is after 2 March 2015. For both the Consumer Healthcare busines	SS
contributed by Novartis into the joint venture and the Vaccines business acquired I	
we are reporting all Transfers of Value made under arrangements set up after integ	gration
of the relevant business.	
Multi-year Transfers of value are reported on the relevant reporting date (payment date/ever	nt date)
contracts irrespective of the duration of the contract.	